Sökning: id:"swepub:oai:DiVA.org:uu-488934" >
Ulcerative colitis ...
-
Dahlgren, DavidUppsala universitet,Institutionen för farmaceutisk biovetenskap,Translationell läkemedelsutveckling
(författare)
Ulcerative colitis progression : a retrospective analysis of disease burden using electronic medical records
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2022-10-18
-
Upsala Medical Society,2022
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-488934
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-488934URI
-
https://doi.org/10.48101/ujms.v127.8833DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:151098004URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Ulcerative colitis (UC) is a debilitating inflammatory bowel disease. Present knowledge regarding UC disease progression over time is limited.Objective: To assess UC progression to severe disease along with disease burden and associated factors.Methods: Electronic medical records linked with Swedish national health registries (2005-2015) were used to identify disease progression of UC. Odds of all-cause and disease-related hospitalization within 1 year were compared between patients with disease progression and those without. Annual indirect costs were calculated based on sick leave, and factors related to UC progression were examined.Results: Of the 1,361 patients with moderate UC, 24% progressed to severe disease during a median of 5.2 years. Severe UC had significantly higher odds for all-cause (OR [odds ratio] 1.47, 95% CI [confidence interval]: 1.12-1.94, P < 0.01) and UC-related hospitalization (OR 2.47, 95% CI: 1.76-3.47, P < 0.0001) compared to moderate disease. Average sick leave was higher in patients who progressed compared to those who did not (64.4 vs 38.6 days, P < 0.001), with higher indirect costs of 151,800 SEK (16,415 ) pound compared with 92,839 SEK (10,039 ) pound (P < 0.001), respectively. UC progression was related to young age (OR 1.62, 95% CI: 1.17-2.25, P < 0.01), long disease duration (OR 1.09, 95% CI: 1.03-1.15, P < 0.001), and use of corticosteroids (OR 2.49, 95% CI: 1.67-3.72, P < 0.001).Conclusion: Disease progression from moderate to severe UC is associated with more frequent and longer hospitalizations and sick leave. Patients at young age with long disease duration and more frequent gluco-corticosteroid medication are associated with progression to severe UC.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Agreus, LarsKarolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden.
(författare)
-
Stålhammar, JanUppsala universitet,Allmänmedicin och preventivmedicin(Swepub:uu)janstalh
(författare)
-
Hellström, Per M.,1954-Uppsala universitet,Gastroenterologi/hepatologi(Swepub:uu)perhe742
(författare)
-
Uppsala universitetInstitutionen för farmaceutisk biovetenskap
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Upsala Journal of Medical Sciences: Upsala Medical Society127:10300-97342000-1967
Internetlänk
Hitta via bibliotek
Till lärosätets databas